Teva

Teva share price at 6-year high after trial results

Read more

Teva jumps sharply on bowel disease drug results

Read more

Teva divests from Japanese JV with Takeda

Read more

Despite price cuts, Teva loses its shine in Israel

Read more

Teva reports seventh straight quarter of growth

Read more

Teva leapfrogs Check Point as Israel’s most valuable company

Read more

Teva settles further price-fixing lawsuits in the US

Read more

Teva shareholder sues after $450m US settlement

Read more

Teva settles opioid suits in Israel

Read more

Teva reports strong Q2 results, raises 2024 forecast

Read more